StockData
ImmunityBio, Inc. logo

ImmunityBio, Inc. (IBRX) stock

IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$6.26+0.28 (+4.68%)

Close on Nov 17, 2026Market cap $6.63BP/E –Yield –

Earnings

ImmunityBio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 14, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$48.84M
EPS, Q3 FY2026
-$0.18
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of ImmunityBio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Jan 14, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026before the open$48.84M–-$0.18Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$44.21M+167.9%-$0.62Release
Q4 FY2025ended Dec 31, 2025Jan 15, 2026before the open$38.30M––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close–––Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$26.40M–-$0.10Release
Q1 FY2025ended Mar 31, 2025Apr 15, 2025before the open$16.50M––Release
Q4 FY2024ended Dec 31, 2024Mar 3, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open–––Release
Q4 FY2022ended Dec 31, 2022Feb 14, 2023after the close–––Filing
Q3 FY2022ended Sep 30, 2022Dec 12, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

ImmunityBio has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When ImmunityBio puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases ImmunityBio filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Update
  6. Update
  7. Results
  8. Results
  9. Update
  10. Update
  11. Results
  12. News
  13. Results
  14. News
  15. News

See a number that looks wrong?